Funding for this research was provided by:
National Cancer Institute (P50 CA244690)
Received: 8 June 2021
Accepted: 21 June 2021
First Online: 15 July 2021
: Not applicable.
: This trial was approved by the Penn IRB. Participant consent was ascertained for the interviews.
: Dr. Schnoll has provided consultation to Pfizer, GlaxoSmithKline, and Curaleaf and has received free medication and placebo from Pfizer for past studies. Dr. Asch is a partner at VAL Health. Dr. Beidas receives royalties from Oxford University Press. She has provided consultation to the Camden Coalition of Healthcare Providers. She currently consults to United Behavioral Health and serves on the Clinical and Scientific Advisory Board for Optum Behavioral Health. Dr. Bekelman reports grants from Pfizer, grants from UnitedHealth Group, grants from Embedded Healthcare, grants from Blue Cross Blue Shield of North Carolina, personal fees from UnitedHealthcare, personal fees from CMS, personal fees from NCCN, personal fees from Optum, personal fees from CVS Health, personal fees from Astrazeneca (indirect via NCCN), outside the submitted work.